🔎 Trials Near Me

Home › Gastrointestinal Stromal Tumors › Massachusetts › Boston

Gastrointestinal Stromal Tumors clinical trials in Boston, MA

7 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

RecruitingPhase 3
  • GSK Investigational Site, Boston
  • GSK Investigational Site, Boston
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07218926

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07406633

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingPhase 2
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

PH 2 Pemigatinib in SDH-deficient GIST

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07434843

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06630234

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
  • Harvard University, Boston
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06655246

Gastrointestinal Stromal Tumors trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.